AGENTS AND DEVICES FOR USE IN PREVENTION OF RESTENOSIS

1 . A device for use in a lumen of a vessel, comprising one or more drugs selected from the group consisting of 8-Azaguanine, Amodiaquin Dihydrochloride Dihydrate, Atovaquone, Betulin, Chlorambucil, Ciclopirox Ethanolamine, Cis-(Z)-Flupentixol Dihydrochloride, Clofilium Tosylate, Deferoxamine Mesylate, Doxazosin Mesylate, Esculetin, Monobenzone, Nifedipine, Primaquine Diphosphate, Securinine, Syrosingopine, Terconazole, a colchicine analog as defined in Structure I

wherein

R 1 and R 2 are independently H, C 1-10 alkyl, C 1-6 cycloalkyl, C 1-10 alkenyl, C 1-6 cycloalkyl, C 1-6 cycloalkenyl or C 1-10 alkynyl, or together form a ring containing from 3 to 6 carbon atoms; provided that a carbon atom comprising an alkene or alkyne bond of R 1 and R 2 is not also simultaneously bound to N;

R 1 and R 2 optionally may be substituted with one or more of F, OR 9 , or NR 10 R 11 where R 9 , R 10 and R 11 are independently H or C 1-5 alkyl;

R 3 is H, C 1-10 alkyl, C 1-6 cycloalkyl, C 1-10 alkenyl, C 1-6 cycloalkyl, C 1-6 cycloalkenyl or C 1-10 alkynyl;

X is O or NOR 9 ;

R 4 is H; OR 9 , provided R 9 is not CH3; SR 9 ; NR 1 R 2 and

R 5 is H, OR 9 , SR 9 , NR 1 R 2 ; and

R 6 , R 7 and R 8 are independently H or C 1-5 alkyl, or R 6 and R 7 or R 7 and R 8 independently together form a cycle containing 1 or 2 carbon atoms,

and a colchicine analog as defined in Structure II

wherein

R 1 and R 2 are independently H, C 1-10 alkyl, C 1-6 cycloalkyl, C 1-10 alkenyl, C 1-6 cycloalkyl, C 1-6 cycloalkenyl or C 1-10 alkynyl, or together form a ring containing from 3 to 6 carbon atoms; provided that a carbon atom comprising an alkene or alkyne bond of R 1 and R 2 is not also simultaneously bound to N. R 1 and R 2 optionally may be substituted with one or more of F, OR 9 , or NR 10 R 11 where R 9 , R 10 and R 11 are independently H or C 1-5 alkyl;

R 3 is H, C 1-10 alkyl, C 1-6 cycloalkyl, C 1-10 alkenyl, C 1-6 cycloalkyl, C 1-6 cycloalkenyl or C 1-10 alkynyl;

X is O or NOR 9 ;

R 4 and R 5 are H, OR 9 , SR 9 , NR 1 R 2 ; and

R 6 , R 7 and R 8 are independently H or C 1-5 alkyl, or R 6 and R 7 or R 7 and R 8 independently form a cycle containing 1 or 2 carbon atoms.

2 . The device of claim 1 , and further comprising therein an anti-inflammatory, anti-thrombotic or pro-healing agent.

3 . The device of claim 1 , wherein said drug is selected as one defined in structure I, or a pharmaceutically acceptable salts thereof.

4 . The device of claim 3 , wherein

R 1 and R 2 are independently H, C 1-10 alkyl, or C 1-6 cycloalkyl

R 3 is H;

X is O;

R 4 is H; OR 9 , provided R 9 is not CH 3 ; SR 9 ; or NR 1 R 2

R 5 is H; and

R 6 , R 7 and R 8 are independently H or C 1-5 alkyl.

5 . The device of claim 4 , wherein R 1 and R 2 are H, R 4 is OH and R 6 , R 7 and R 8 are H or CH 3 .

6 . The device of claim 1 , wherein the drug is selected according to Formula I and has the structure

7 . The device of claim 1 , wherein said device contains one or more active agents and a compound of structure II or pharmaceutically acceptable salts thereof of.

8 . The device of claim 7 , wherein

R 1 and R 2 are independently H, C 1-10 alkyl, or C 1-6 cycloalkyl

R 3 is H;

X is O;

R 4 is H, OR 9 , SR 9 , or NR 1 R 2 ;

R 5 is H; and

R 6 , R 7 and R 8 are independently H or C1-5 alkyl.

9 . The device of claim 8 , wherein R 1 and R 2 are H, R 4 is OH or OCH3, and R 6 , R 7 and R 8 are H or CH3.

10 . The device of claim 9 , wherein the compound has the structure

11 . A method of use of a device according to claim 1 , wherein said device is a stent and comprising the step of inserting said stent inserted into a subject in need thereof.

12 . A method for reducing the incidence of restenosis, said method comprising the steps of:

(a) providing a stent or other device as defined in claim 1 , and

(b) implanting said stent or other device into the vasculature of a patient in need thereof.

13 . The device of claim 1 which is a stent.

14 . The stent of claim 13 combined with a biologically active agent selected from the group consisting of an anti-inflammatory agent, a pro-healing agent, a lipid metabolism modulating agent and an anti-thrombotic agent.

15 . The stent of claim 13 wherein said drug has as defined in structure I or a pharmaceutically acceptable salts thereof.

16 . The stent of claim 14 , wherein

R 1 and R 2 are independently H, C 1-10 alkyl, or C 1-6 cycloalkyl;

R 3 is H;

X is O;

R 4 is H; OR 9 , provided R 9 is not CH3; SR 9 ; or NR 1 R 2

R 5 is H; and

R 6 , R 7 and R 8 are independently H or C1-5 alkyl.